BioSpace News Archive

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that Chief Executive Officer Raymond W. Cohen is scheduled for a fireside chat at the Barclays Global Healthcare Conference,

AIS Healthcare has announced the acquisition of Hunt Valley PharmaLAB (“Hunt Valley”), a 503A compounding pharmacy focused on ophthalmology medications.

Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced the publication of nonclinical data on the mechanism of action of nesolicaftor (PTI-428).

With the release of Ansys® RaptorH™, Ansys (NASDAQ: ANSS) will empower engineers to accelerate and improve 5G, three-dimensional integrated circuit (3D-IC) and radio-frequency integrated circuit design workflows for innovations like smart devices, antenna arrays and data storage systems.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that management will present company overviews at the following conferences

Bit Bio announces agreement with Abcam, a global innovator in life science reagents and tools, to make Bit Bio’s iPSC derived functional human cells widely available to the global life science community.

Aria CV, Inc., a developer of medical devices treating Pulmonary Arterial Hypertension (PAH), today announced that it has completed a $31 million Series B round of financing to fund its first clinical study in the United States.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced it has reached the 100 patient enrollment target for the Marigold Study.

Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF) (“Aleafia Health” or the “Company”) will announce its 2019 fourth quarter and fiscal year results on March 18, 2020 prior to market open.

Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today reported financial results for the fourth quarter and full year ended December 31, 2019.